Revolution Medicines rallies after phase 3 pancreatic cancer trial doubles survival versus chemo

Revolution Medicines Inc. RVMD shares are up during Monday’s premarket session following positive topline results from its ...

Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?

Revolution Medicines stock rallies on impressive daraxonrasib Phase 3 results. Here’s why RVMD shares may sustain the ...

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, ...

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026

Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026Praxis to ...

Eli Lilly's Jaypirca builds case with fourth positive phase 3 trial in blood cancer patients

Eli Lilly and Co. LLY shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the ...
Fierce Biotech

Takeda clears path to FDA with phase 3 data on $4B psoriasis bet

With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its ...
Managed Healthcare Executive

Phase 3 trial program begins for investigational sleep medication, alixorexton

Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy ...
Seeking Alpha

Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place

Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...